Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence.

ABSTRACT: BACKGROUND:There is no randomized clinical trials with recurrence of atherosclerotic cardiovascular disease (ASCVD) as a major outcome with rosuvastatin. In order to analyze potential differences in the clinical response to atorvastatin and rosuvastatin in secondary ASCVD prevention, we have analyzed the clinical evolution of those subjects of the Dyslipemia Registry of the Spanish Society of Arteriosclerosis (SEA) who at the time of inclusion in the Registry had already suffered an ASCVD. METHODS:This observational, retrospective, multicenter, national study was designed to determine potential differences between the use of atorvastatin and rosuvastatin in the ASCVD recurrence. Three different follow-up start-times were performed: time of inclusion in the registry; time of first event if

SUBMITTER: Perez-Calahorra S 

PROVIDER: S-EPMC6905000 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature